nm0607: right then [0.4] okay that's great [0.8] yeah so i said in Finland [0. 8] about thirty per cent of cases are only thirty per cent of cases are acquired out of country and the rest acquired in country [1.5] so the next thing i want to show you is the [1.6] it says the situation in the U-K [0.6] er [0.5] current situation in the U-K [1.3] er that's a bit grim [2.8] er [1.5] i was just going to explain [6.5] you've got them in your handout [0.3] sm0608: yeah sf0609: u-huh nm0607: [4.7] now [1.7] i haven't put them on this copy i can't get onto my hard disk it's er [1.0] let's shut this off a minute and we'll talk about that when we move on nm0607: so if we look at the first table this this gives you the most up to date information for the U-K [0.4] okay [0.6] and what you can see is cumulatively [1.6] at the end of last year [1.4] about fifty-two-thousand people [0.8] had been diagnosed or fifty-three-thousand almost fifty-three- thousand down in the bottom [0.3] right-hand corner [0.4] had been diagnosed with H-I-V [1.0] and of those roughly thirty-thousand [1.1] were homosexual spread [1.2] men-men [1.0] and roughly fifteen-thousand so slightly under a third [0.9] were [0.2] heterosexual spread [1.0] and then [0. 6] intravenous drug abuse comes next and then a relatively small number from blood products [0.6] about a thousand just under a thousand mother to infant transmission and then a couple of thousand where it's not quite clear how the transmission occurred [0.9] the thing that you should notice along the bottom [1.1] is that up until around about ninety-ninety-seven [1.0] the number of newly acquired infections each year is relatively stable [1.0] and then it starts to accelerate again [0.8] and in fact in the period September two- thousand-and-one to September two-thousand-and-two [0.4] there's been some five- thousand-three-hundred [0.4] new [0.6] infections diagnosed [1.4] so you can see that after a period of about ten years of relatively stable new infection rates [1.2] the epidemic is [0.4] in this country [0.3] is increasing again [0. 2] not dramatically but it is going up at the rate of [0.6] roughly [0.8] fifteen to twenty per cent increased incidence a year [2.8] and if you look at table two [2.3] what table two shows you is [0.9] diagnosis by [1.0] exposure category [2.0] for [0.6] just for one year just for the last year September [0. 5] two-thousand-and-one to September two-thousand-and-two [2.5] and you can see that [1.3] this sh-, this [0.8] table shows you two things it shows you [0.7] the distribution according to what type of category the infection was [0.6] in so men-men [0.6] and heterosexual spread and various subdivisions of heterosexual spread and you can see in there the figure that shows [1.0] for heterosexual er s-, er spread acquired abroad [0.7] no evidence of a high risk partner [0.9] okay [0.6] acquir-, U-K acquired no evidence of a high risk partner [0.7] and you can see it broken down by region [1.5] and the thing i want to come out of the broken down by region is you can see that both in terms of [0.5] the acquired infections last year and the total number of infections acquired [1.0] London is an epicentre [1.3] yeah [3.5] and then the final table i've given you [3.1] is [1.0] again [0.2] year is is more total figures this is [0.4] year of infectio-, [0.5] year of infection over the last ten years [1.5] and the area where the infection was acquired [0.3] or was diagnosed in fact not necessarily acquired [0.5] and again what emerges from that is you can see that across the total epidemic of the [0.3] fifty-odd- thousand cases [0.8] some were over thirty-thousand thirty-two-thousand [0.4] were acquired in the London area [1.7] what that's telling you is [0.4] even in the epidemic in this country [0.7] the [0.2] the risk [0.3] varies according to where in the country you are [0.7] okay and that would be true in most countries [0.8] risk is not uniform [1.3] okay and it's it's a it's an important message to get across to you [2.7] okay [0.8] so you can see the situation globally [0.6] is we've got some forty-million people [1.5] infected [0.9] but actually the U-S-A the U-S the U-K's contribution to this forty- million [0.5] is pretty small [0.7] it's only fifty-two-thousand [1.8] in fact it's less than fifty-two-thousand really because [0.5] you're talking about [0. 5] a significant fraction of the fifty-two-thousand diagnosed cases in this country will already be dead i can't remember [0.4] what the total is it's around about thirty-thousand of them have already died [0.8] so we're only contributing about twenty- thousand [0.6] between twenty and thirty-thousand [0.2] to that forty-million figure [0.7] in this country [1.6] okay [1.4] all right that's all i'm going to say about the [1.0] the epidemic [0.8] okay [0.7] the important message you've got to take across about the epidemic is [1.1] it's a c-, huge global problem [1.5] it's still an escalating grobal problem [1.1] okay [0.2] the numbers are going up rapidly they are not stable or going down [0.7] okay [0.6] and it's predominantly a problem in the developing world [0.9] particularly sub-Saharan Africa [0.7] where you've seen from some of the incidence figures i showed you in the last lecture [0.5] that there are quite frightening consequences for social structures in some of those countries [0.9] you know [1.6] er [0.4] less of a problem in the developed world more under control in the developed world [1.1] more under more un-, control more under control still in this country [1.3] most of the spread in this country is still [0.3] homosexual spread although heterosexual spread [0.3] is the most rapidly growing [0.2] category [1.3] and most of that heterosexual spread [0.5] is [0.2] infection acquired [0.2] out of the country [1.0] so by somebody going from this country and having a sex partner [0.3] in a country where the generalized epidemic is a-, is going on [0.3] at a high level [0.8] rather than spread within the country [2.2] all right what i want to do now is move away from talking about the epidemic in a broad sense and start talking about [0.5] the virus [1.2] okay and the infection [0.7] so we have another [0. 4] chunk of handouts and i'll try and get [0.6] this up while you hand those around [2.6] if i can find me [0.2] pointer again [1.3] i've put the bally thing down [0.2] here we go nm0607: right [2.4] i hope you will already have seen a v-, [0.2] a version of this sort of slide maybe not a precisely [0.2] this but a version of this [0.8] so this is the virus we're talking about H-I-V [0.8] H-I-V [0.3] is a retrovirus to remind you [0.6] what that means is that is that unusually for a vir-, oops let me back up here [7.2] oh [0.2] bother [5.1] unusually for a virus it has a diploid genome [0.2] there are two pieces [0.6] of single strand [0.8] positive sense [0.5] R-N-A [0.4] contained within the virus particle [5.1] the R-N-A is approximately ten kilobases in length [0.6] just under ten kilobases in length [2.0] it is [0.5] it is surrounded [2.0] by a [0. 6] capsid structure [0.9] composed of [0.6] a number of proteins [0.6] P-twenty- four being the major protein [0.9] and when H-I-V is diagnosed [0.9] it is in fact antibodies against P-twenty-four [1.2] that form the main basis of [0.3] diagnosis [2.8] so [0.2] the bulk of H-I-V diagnosis does not involve [0.3] looking directly for the agent itself for looking for the virus itself [0.6] that usually comes [0.3] as a confirmatory test [0.8] the bulk of diagnosis is looking [0.3] by looking for antibodies against this [0.4] major structural protein [0.9] P-twenty-four [0.5] that makes up the inner capsid shell [3.5] this [0.6] capsid shell has a toroid [0.2] type of structure a sort of [0.3] bit like a a flattened ended cone [2.8] m-, [0.7] on the R-N-A is the reverse transcriptase enzyme [1.1] this is a retrovirus so which group in the Baltimore classification scheme is this in [0.6] sm0610: six [2.2] nm0607: didn't hear it very loud [0.3] sm0610: six nm0607: six that's right six [0.7] so it goes through a D-N-A intermediate so the first thing that it's got to do when it gets inside the infected cell is convert its [0.5] single strand [0.4] positive sense R-N-A [0.5] into duplex D- N-A [0.6] and it's transcription from that duplex D-N-A [0.6] that gives rise to the viral messenger R-N-A [2.5] the [1.1] toroidal [0.2] capsid is surrounded if i can ever find my pointer again there we go [0.4] is surrounded by matrix protein [0.7] shown here in green [1.4] that's then surrounded by a lipid envelope [0.3] so this is a lipid containing virus [1.3] and embedded in that lipid envelope [0.5] is the [0.6] envelope protein of the virus [1.1] and the envelope protein is synthesized as a precursor [3.7] called G-P- [1.4] one-sixty [1.5] the G-P standing for glycoprotein because this envelope [0.7] protein [0.5] is a glycoprotein [1.2] and after synthesis G-P-one-sixty is cleaved [0.8] to produce G-P-one-twenty [1. 0] which forms the head [2.4] of the [2.0] envelope protein sticking outside the lipid envelope [1.9] and G-P-forty-one which is kind of like the stalk [1. 3] that through non-covalent interactions [0.3] holds the [0.3] G-P-one-twenty in place [0.7] and the G-P-forty-one is a transmembrane protein it [0.2] it goes through the lipid bilayer membrane [2.0] okay [1.0] down here at the bottom [1.6] is the gene organization [0.3] of this virus [2.1] and [1.3] it's like any other retrovirus it [0.6] but has some additional genes what genes do normal retroviruses carry [1.9] sf0611: gag pol and env [1.0] sm0612: gag pol and env nm0607: gag pol and env and you can see here [0.9] gag [1.3] pol [1.1] and env [1.2] okay [0.7] but H-I-V is unusual in having a number of othe-, additional proteins usually referred to as accessory proteins [3.1] and the degree to which we understand what these accessory proteins actually do for the virus [0.5] varies according to which protein we are talking about [1.5] so for example you will already have heard in this lecture series quite extensively about tat and rev [1.0] tat and rev are involved in the regulation of gene expression by this virus [0.9] okay [0. 7] but you won't have heard anything yet for example [0.5] about vif [1.4] okay [0.8] vif is another accessory protein [0.4] that overlaps [0.3] the carboxy terminal end of the coding region of [0.9] the R-T gene the polymerase gene [0. 7] and the amino terminal region of the V-P-R gene [1.8] and vif stands for virus infectivity factor [4.5] it's the protein that m-, [0.3] of H-I-V that the limited amount of H-I-V work that i do that's the protein that we work on vif is an interesting protein [0.5] in that [1.7] as the name implies it's required [0.6] for virus infectivity [1.6] and if this protein is absent [0.9] and you try and grow virus in the [2.5] normal host cells for this virus [0.7] which are C-D-four- positive lymphocytes [0.5] then the progeny virus that is produced is non- infectious [4.5] it turns out [0.7] that vif [0.5] is actually required to overcome a normal cellular [0.4] protein that's an inhibitory factor [0.7] for H-I-V replication [0.9] and i don't have time to go into the detail and anyway the detail is not pertinent to [0.2] the rest of what i'm going to say [1.0] so there are a number of accessory proteins down here [1.4] and three [0.4] major normal retrovirus proteins gag which m-, [0.6] is a [0.4] er [1.2] is made as a polyprotein initially [1.3] called [3.2] er [3.0] P-R-fifty-five [1.3] 'cause of the fifty-five kilodalton [4.2] precursor [1.0] and that precursor is cleaved through the action of a [0.5] virion encoded protease gene [1.6] that undertakes the major cleavages necessary to convert [0.7] P-R-fifty-five [1.0] into [1.3] P-seventeen P-twenty-four P-six P-one P-seven a number of [0.8] structural proteins that make up this [0.3] capsid shell here that i'm pointing to [2.9] okay [1.5] so that's the virus we're talking about [1.3] let's move on then to look at the pattern of this infection [4.2] now you can divide H-I-V infection [0.8] into three broad stages [1.9] there's the primary infection [2.3] which occurs over a few weeks [2.6] there's a long period of what is usually called clinical latency [2.9] and then there's the [0.5] terminal stage of disease [0.4] which we usually refer to as AIDS [2.4] and the important point to see down here is the scale [1.9] you can see that the primary infection [0.7] occurs over a matter of weeks [2.8] the latent period [1.8] can be years [0.8] there are certainly people around who have [0.7] been well [0.5] for more than a dozen years [0.7] and then for some reason that's not entirely clear [0.4] gone into full-blown AIDS [2.5] the point about this [1.3] is [0.2] once you go into AIDS you are going to die [1.2] okay [1.7] you may you may be it may be possible to hold you [0.9] through [0.2] using antivirals that i'll talk about in a minute [1.0] in [0.2] in some sort of semblance of reasonable health for a period of time [1.4] but for example [0.5] when [0.5] A-Z-T zidovudine the main [0.3] R-T antiviral inhibitor was u-, used extensively in the United States in monotherapy [0.9] it improved your life expectancy as an AIDS victim from ten months to twenty months [2.1] so it had an effect [0.5] one shouldn't underestimate its effect [0.7] but [0.8] it didn't mean that you were going to survive [0.9] for [0.2] a long period of time and have a natural lifespan [1.4] okay i want to talk [0.8] a little bit about [0.4] the division of these different [0.6] er stages of the disease [0. 8] by symptomology [1.6] and [0.3] this really [2.3] deals with the [0.3] the clinical pattern of disease [0.9] okay [1.3] and i want to [0.3] keep referring back to this as i talk about the clinical pattern of disease [0.4] okay [1.7] now of course once [0.6] people started to diagnose H-I-V it became important [0.5] to have available to clinicians [0.4] some sort of definition [0.9] of what stage of this process [0.4] a particular patient that might present to them [0.5] was at [0.7] okay [0.8] and [0.4] two systems grew up [0.7] quite quickly [0.6] one was proposed by the C-D-C the Centre for Disease Control remember the place in Atlanta i said that is the sort of [0.3] American equivalent of the P-H-L-S [1.1] okay [1.3] and the other grew up [1.2] through [0.5] a major [0.2] hospital in the United States in Washington called the Walter Reed Hospital now the Walter Reed Hospital has a very long history of dealing with tropical diseases [1.4] okay [0.9] and these two [0.8] er organizations proposed a staging [0.9] system [0.4] to allow clinicians to [1.0] define when a patient presented to them what stage of disease that patient was in [1.5] the C-D-C system [2.1] defined people [0.7] as being in stage one [0.6] through [0.2] to four [1.3] and this was romanic one through to romanic four [4.2] the Walter Reed system [0.7] allowed you to divide people [0.3] in a stages zero to six [6.9] now it's important of course [0.4] when a new disease comes along [0.2] to have some sort of system of clinically defining the disease [0.5] why is that [belch] important excuse me [0.7] well it allows you to do surveillance studies that's the first thing it allows you to do it allows you to actually survey the disease [0. 8] particularly when you've got a disease that you know is going to [0.6] is going to develop over a long period of time [0.9] it allows you to survey its development [0.5] it allows you to do epidemiological studies what is the incidence of infection [1.5] and of course it will if you've got some sort of therapeutic intervention metha-, measur-, measure method [0.4] it will allow you to measure how how good that therapeutic intervention is [2.0] now these two schemes the C-D-C scheme [1.6] and the Walter Reed scheme [1.6] when they were first proposed [1.0] in the middle nineteen-eighties they were both used [3.1] they each have advantages and disadvantages [1.8] the C-D-C system [0.9] is largely based on clinical observation of the patient [3.0] so basic simple clinical observation of the patient [1.1] weight [1.1] er symptomology [1.1] okay [0.5] very little lab very little involvement of lab indicators or immune system indicators [1.2] by contrast the Walter Reed system [0.7] is ba-, is mainly based [0.4] on laboratory diagnostic assays [6.3] now on a global scale [0.6] the C-D-C system [0.7] took over relatively quickly [0.9] from the Walter Reed system and the main reason for that [0.2] was because [0. 6] the disease grew rapidly [0.4] in countries that were not well set up [0.5] to do the laboratory diagnostic assays that could easily be done in the United States [1.5] and so the C-D-C system is the system that you will most often hear about today and is the system that's broadly used [0.4] to define what stage someone is in [3.7] so [0.3] in this system then stage one [4.0] is the acute [0.4] phase of infection [6.6] and this acute primary infection [0.6] period [1.3] is most usually asymptomatic [2.2] so the person is infected [1.6] but most commonly they have no idea that they are infected they they exhibit no symptomology [1.0] if they do exhibtib-, er exhibit symptomology [0.7] it's basically a flu-like syndrome [2.1] they might get some fever they might get a bit of nausea they might be a little bit lethargic perhaps a little bit of diarrhoea [0.4] a sore throat et cetera [0.8] but nothing that's very specific i mean there are lots of things that would cause that [0.8] you know a bad night on the bevvy would cause most of those symptoms [0.3] okay so [0.6] in the acute phase there really er ev-, if there's any symptomology at all [0.8] it's nothing that you can kind of put your finger on and say ah you know i know this person is probably infected with H-I-V because they've got this symptom [1.1] okay [3.1] the only lab indicators you get in this acute phase [0.3] are a transient leukopenia and lympha-, [0.2] lymphopenia [1.2] so a transient drop leukope-, penia [0.5] means drop basically [1.0] so a transient drop in leukocyte numbers and lymphocyte numbers [5.7] you might get an inversion [0.9] of the ratio of C- D-four to C-D-eight cells in the bloodstream [2.7] but it's important to realize that at this stage in the fect-, infection that is not due to a drop in C-D-four cells it's due actually to an increase in C-D-eight cells [6.9] okay [1.7] you may see some atypical lymphocytes in blood smears but you may not [1.7] okay [0.3] so the picture i'm painting then of stage one [0.6] is somebody who's infected [2.1] probably has no idea they're infected has no symptomology [1.7] okay [1. 4] and will take [0.5] somewhere between [1.6] a few days [1.2] and as long as three months [1.4] to seroconvert [2.9] now you remember i said to you that when people are diagnosed as being H-I-V positive [0.8] the main form of diagnosis is seroconversion the production of antibodies against one of the structural proteins of the virus [2.1] so in the period up to three months [0. 8] after the person has been infected [1.5] there are probably no indicators either to that individual [1.7] through symptomology or indeed [0.5] to the health authorities [0.6] through some sort of diagnostic assay [0.2] that they've actually been infected [2.8] unless [0.6] the diagnosis is looking specifically for virus [1.8] the reason for that is as you can see [0.5] from the virus count here in the blue line [0.7] it is during this period [1.4] that virus titres in the bloodstream [0.7] are probably at their highest level until you get right to the terminal stages of disease [3.3] okay [1.2] so what does that tell you about this individual [0.8] in terms of [0.4] societal risk [2.5] sm0613: they're at their most infectious [0.3] nm0607: yeah and [0.8] sm0613: they don't know [0.4] nm0607: and what does that mean for society [0.5] sm0613: that [0.2] you're going to get a lot of spread [0.4] nm0607: exactly [1.3] it's people in this phase here [1.0] that as far as society is concerned [0.3] are the greatest danger to society [1.5] okay [0.9] because these people [0.9] don't know they're ill [1.3] don't know that they've become infected [0.9] are probably con-, going to continue in the lifestyle that they had [0.3] prior to getting infected [1.0] and so are probably going to continue to do [0.8] the very acts that resulted in them being infected and so are very much more likely [0.5] to infect other people and they're particularly likely to infect other people [0.4] because they have the highest level of virus [0.3] in their bloodstream so they have the greatest chance at this point [0.4] of passing on the infection [2.5] okay [5.9] as far as seroconversion is concerned okay [0.8] what is the first antibody you would expect to detect after a seroconversion [3.3] what are the main classes of antibody that you get in the bloodstream [2.5] there are three [2.9] huh [0.9] sf0614: I-G-G [0.5] nm0607: I-G-G's one [0.9] sm0615: I-G-M [0.3] nm0607: I-G-M's two [2.6] what's the third one [1.6] sm0616: I-G-N [0.5] nm0607: I-G sm0616: N nm0607: okay so which out of these three then [0.5] are you most likely to detect [0.7] first [1.8] after infection [0.5] sf0617: I-G-M sm0618: I-G-M [0.9] nm0607: are we sure about that [0.3] sm0618: [0.9] nm0607: yeah [0.5] sf0617: yeah [1.5] nm0607: well you're right what happens with I-G-M remember [0.5] is I-G-M is the antibody that's initially produced to an infection [0.5] it rises very rapidly [1.0] you can often detect an I-G-M response [0.3] in [0.3] a few days [0.7] in the case of H-I-V you may un-, [0.2] you may intec-, detect an I-G-M response in as little as five days post-infection [0.6] if you go looking for it [2.2] it peaks [0.6] at about twenty-four days [0.3] plus or minus seventeen [2.4] and it disappears it goes back down again remember I-G-M drops away again [0.8] and it disappears by day eighty-one [0.2] plus or minus twenty-seven days [4.0] so [0.6] if you go looking for I-G-M [0.3] to H-I-V [0.3] four months after infection you won't find it right [0.5] it's gone [2.1] I-G-G [1.7] can be [0.3] most early detected about eleven days [0.6] so [0.4] almost two weeks after initial infection [1.8] it doesn't peak [0.7] to a hundred-and-thirty- three days plus or minus sixty-three days [7.9] so it's about three months [0. 7] after the person's infected [0.9] that I-G-G the stable long term antibody response that you will see in a human [1.4] peaks [1.3] okay [1.1] so that's all i'm going to going to stay about stage one [1.5] other than to say that [1.7] you must [0.3] notice [0.3] that what happens at the end of stage one as far as the virus titre is concerned [1.0] is that it drops [2.1] and you should remember that this graph over here [0.6] the virus titre is a log scale [1.9] so it's a it's [0.2] it's a little bit misleading to look at this graph and think oh well it doesn't actually go down very much [1.9] it drops about a hundredfold [2.1] to a thousandfold in terms of titre [0.9] that means that at the end of the acute phase [0.6] the person is going to be [0.2] a hundred to a thousand times less likely [0.7] to transmit the virus [0.7] than they are at the peak of the acute phase [2.2] this drop in virus [0.5] is as a response of the immu-, is is [0.8] comes from the immune response [0.8] that has been activated against the virus both a [0.3] humoral and cell- mediated immune response [0.7] that is able to some degree to get the virus under control and eliminate it [1.5] but the crucial thing is it's to some degree [1. 7] like all persistent virus infections [0.4] the immune response in this case is not able to completely eliminate the virus [2.9] it gets it under control but it doesn't eliminate it [3.1] okay [0.4] so that takes us from stage one then [0.5] into stage two [2.8] now stage two of infection [0.7] is this period of what is usually referred to as clinical latency [5.8] now what you can see in clinical latency [1.8] is that first of all it can be very long [2.1] okay [1.2] it can also be relatively short [3.0] so of course when it was realized [1.2] that this period [1.1] was of variable [1.2] and somewhat indeterminate length [1.1] the first thing that people started looking for [0.6] were prognostic indicators [2.0] was there any indicator during this period [0.7] that would tell you how long it's going to last [2.8] and why would that be important well it would be important because [0.4] during this period [0.5] the people are well [2.0] they're not a-, they're not exhibiting any disease symptoms [0.3] they are well [1.2] okay [0.8] if you acquire the infection [0.6] at twenty years of age [1.0] and somebody sells you well according to your prognostic indicator [0.4] you're not likely to go out of this [0.2] period of clinical latency for fifty years [0.9] you're not going to worry about it too much right 'cause you're probably going to be killed by something else before you get to seventy [0.6] yeah [0.7] but if somebody says to you [0.4] according to your prostic-, prognostic indicators your clinical peri-, period of clinical latency is going to be two years [1.2] then you're going to start [0.2] you know living life and spending money pretty quick because in five years you're going to be dead [0.4] probably in four years you're going to be dead [0.6] okay [1.5] i i've i've laid it out in a in a dramatic fashion [0.3] so that you realize that there was an enormous amount of pressure in the mid-eighties [0.4] to try and come up with prognostic indicators because that's what people were worried about [1.0] i am sick doctor you know [0.3] i am infected with something doctor when am i going to get sick is the question that was being asked [0.7] okay [1.9] now what you can see that is going on during this period [1.1] is [0.6] there is a very slow but almost imperceptible rise [0.6] in the viral load [2.7] the level of virus in the bloodstream [1.4] okay [3.4] but at the same time there is a clear drop going on [1.1] in the level of C-D-four-positive lymphocytes [1.3] in the bloodstream [4.8] and in fact the [0. 4] the first sort of indicator [1.3] that people started to use [4.3] were [2. 9] this level of C-D-four count [0.9] i should just back up a second and just [0.3] tell you a little bit about in the in the epidemic in the United States which was the e-, area where the long ter-, first long term studies were done [1.6] they started by looking at [0.6] about seven-thousand homosexuals [0.6] over a ten year period [0.9] yeah [0.4] so the first ten years from the [0.7] from the [0.3] early nineteen-eighties through to the early nineteen-nineties [0.6] and in that ten year period [2.3] thirty-six per cent of them [0.3] thirty-six per cent of the people had developed AIDS within that ten year period [4.2] forty-four per cent of them [1.0] were showing symptoms of going into AIDS by the end of the ten year period [0.7] so these were people who were recruited early they were already infected early in the [1.1] epidemic [0.5] and followed over ten years [1.4] so by the end of that ten years [0.5] somewhere close to eighty per cent of them [0.9] were already showing symptoms of going into disease [2.7] but twenty per cent of them one in five [0.4] were completely asymptomatic at the end of a ten year period [1.0] and this is in the period where there was really virtually no [1.1] er antiviral immuno-, er antiviral therapy going on [2.0] okay [3.2] now [0.3] prognostic indicator [1.3] C-D-four counts [3.4] people in the early phase [1.5] of [0.7] the next stage stage three [2.0] now stage three if you look at the recent literature [0.4] stage three has kind of fallen into disrepute [1.2] it used to be a period where [0.5] people were said to have what's called either ARC [0.5] AIDS Related Complex [1.9] or P-G-L Progressive Generalized Lymphoadenopathy [3.2] and in a sense what it was measuring was people starting to [0.4] tip over into AIDS [5.6] and [0.9] one study for example [0.6] looking at homosexual men who were already in P-G-L [0.5] so were already at the end of stage two beginning of stage three [1.3] followed them over twenty months so only two-and-a-half years [1.2] and if their C-D-four count at the beginning of that twenty months was less than two-hundred [1.1] per ml [1.9] by the end of the twenty month period sixty per cent of them had progressed to AIDS [3.7] by contrast [0.8] if their [1.5] C-D-four count was greater than three-hundred-and-fifty [1.8] per ml [2.0] only ten per cent of them [0.7] were in full-blown AIDS [2.3] sm0619: sorry what was the percentage of the first one nm0607: sixty [0.2] sixty per cent of the people after twenty months [0.4] were in full-blown AIDS if their C-D-four count at the beginning was this level [1. 8] and [1.0] only ten per cent if it was this level [1.9] it's important to point out to you that in these early studies there was a lot of controversy [0.6] because people were not used to measuring [0.5] C-D-four counts in humans [0.7] and it took a little while to realize that actually your C-D [0.2] your C-D-four count [0.5] actually has a daily rhythm [0.9] it goes up and down each day [0.7] so of course if you were mea-, er d-, the count you were getting would depend on when in the day you measured it so there was quite a lot of confusion in the literature [0.5] 'cause people were quoting different figures because they were measuring the counts at different times of the day [1. 0] okay [1.1] once that was figured out once the diurnal rhythm [0.5] of C-D- four counts were was figured out of course they started measuring at the same time each day [0.3] so they could get comparative data [4.4] so what about [1. 1] so that's stages [0.2] one two and three and as i've said to you [0.6] three [0.5] has largely fallen into disrepute [2.6] that takes us on to stage four [2. 1] stage four [1.4] is [0.4] what is now commonly referred to [1.2] as full-blown AIDS [6.5] how do you define the entry into stage four [0.8] well three main criteria [3.1] have been used [1.3] the first is [1.1] fever for [0.3] persisting for more than a month [6.8] involuntary weight loss [0.2] at greater than ten per cent of baseline [2.3] so this is not somebody going on a diet and managing to lose one stone in ten [0. 7] because they're on a diet this is somebody losing [0.2] one stone in ten without trying [2.2] okay [1.5] and diarrhoea for more than a month [4.1] and you've got to have [1.6] all of these symptoms [1.6] without any other [0.4] concurrent reason other than the fact that you're infected with H-I-V [3.8] so it's not just that you've [0.3] kept on going to the same Indian restaurant and eaten you know a pretty [0.3] nasty meal that's been giving you a [0.2] you know [0.8] bad diarrhoea for a month and you've not learned you know you'd better change your restaurant i mean it's it's [0.4] you haven't got any other reason why this is happening to you other than that you're infected with H-I-V [4.0] okay let's ask something about then the viral dynamics that are going on during these different phases [4.3] if we look at the virus what's going on in in er [0.3] the primary infection phase [3.4] is the virus is growing flat out [0.2] there's no immune response there of a-, of any s-, consequence [0.5] the virus is just growing in a completely unrestricted fashion [0.5] it has a doubling time of about ten hours [1.4] peak viraemia will occur at about three weeks [1. 4] and each infected cell is going to [0.9] seed roughly twenty [1.8] new cells [0.8] to become infected [2.3] but the last sentence is quite important [0.4] the virus load starts to drop rapidly [0.5] as the immune response is activated [0.8] so you should not [0.4] be under the impression that [0.5] the immune response that we amount to H-I-V is completely useless [0.2] it's not [1.2] it does a pretty good job [0.5] at controlling the initial acute infection [1.6] it reduces the viral load between a hundred and a thousandfold [1.2] okay [0.8] the only problem is it doesn't completely eliminate the virus [2.1] during the asymptomatic phase [3.3] you have something like ten-to-the-ten virus particles being made every day [3.2] and you have something like ten-to-the-nine [0.4] C- D-four-positive lymphocytes [0.5] being made and eliminated every day [1.5] so you can see that virus replication [1.2] and elimination because remember if a C-D-four is cell is eliminated you're going to eliminate the virus that's replicating in that cell [1.3] you have a rough balance here [0.9] and this is sometimes referred to as the steady state [4.3] what that means is that [2.0] the whole infection [0.7] is actually being sustained by only about ten-to-the- six to ten-to-the-seven ce-, T-cells in the body [2.3] these are productively infected activated T-cells [4.2] the si-, the size of the latent H-I-V reservoir [2.1] okay [1.1] is mostly in resting T-cells [0.8] and it's about similar in size [8.8] it's important to point out to you [0.2] just to remind you [0.9] that when somebody goes into stage four [1.4] the immune system loses control of the virus replication again [0.8] and virus replication takes off [2. 8] and so in [0.4] stage four [0.5] there's again a s-, [0.2] the previo-, one of the previous slides showed you [0.4] a viraemia a strong viraemia [1.8] okay [1.4] a lot of virus in the bloodstream [1.4] a high chance [1.0] of [0.2] potential virus spread [0.9] if [1.6] the individual was indulging in activities that would be likely to spread the virus [2.0] but remember there's a big contrast [0.7] between somebody who's in the acute phase [0.5] and somebody who's in the symptomatic end phase [1.2] this is essentially a sexually transmitted disease [0.7] if you don't know you're infected [0.5] as will be the case in the acute phase [0.6] you will be undertaking your normal sexual activity be it [0.3] you know once a day once a week once a month once a year [0.6] okay [1.0] if you're in late stage AIDS [1.1] you're not interested in sex i mean sex is the last thing you've got on your mind you know [0.4] you've got on your mind coping with the symptomology [0.4] that you're suffering from [0.5] rapid weight loss [0.6] you've got diarrhoea you've got fever [0.4] as i explained to you on the first lecture you might have an opportusisti-, [0.2] opportunistic infection like athlete's foot up to the knee [0.4] it's sym-, in symptom terms [0.3] it's a very unpleasant er end stage infection [0.9] and so actually people in full-blown AIDS [0.3] are not a major risk [0.7] to society [1.3] they might be a risk to the people who are actually treating them [0.6] and the people who are treating them have to be careful [0. 4] that they don't come into contact with blood [0.9] remember these people may be bleeding from a number of orifices [1.0] but they they don't pose a large risk to society [1.5] okay my time's up i'll stop there and continue next [0.8] Tuesday [0.2] sf0620: mm-hmm [0.2] nm0607: tuesd-, Tuesday i think it is [2.5] okay